Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Questcor Pharmaceuticals acquires rights from Novartis to develop Synacthen
Acquisition of the rights, which is still subject to certain closing conditions, will enable the firm to develop Synacthen and Synacthen Depot in the US as well as
Acquisition of the rights, which is still subject to certain closing conditions, will enable the firm to develop Synacthen and Synacthen Depot in the US as well as
Stating improved product’s indication, the new label provides dosing guidelines for different categories of patients, including those weighing over 100kg. The new indication states, "Acetadote is an antidote
AxION iQT system provides greater quantitative capabilities compared to a triple quad and can identify 500 compounds per second similar to a quadrupole time-of-flight (Q-TOF). The device has
As part of a collaboration between both the parties, which was signed in 2010, Xenon will now be responsible for all future development and commercialization of XEN701. XEN701
Following to completion of review of the Trokendi XR new drug application as revised in December 2012, the regulator approved the product for use as recommended in the
The Protein Purification Facility will leverage the cGMP compatible stable, non-lytic protein expression platform for expression of complex and challenging proteins, including Fab fragments and other proteins. ExpreS2ion
The Irys benchtop instrument is fully automated and uses the IrysChip to uncoil and confine long DNA molecules in Nanochannel Arrays, where molecules are then uniformly distributed in
With an orphan drug status for the treatment of acute myeloid leukemia (AML), the novel targeted therapy is directed to the interleukin-3 receptor (IL-3R) present on tumor bulk
In exchange, BioLineRx will receive an upfront license fee, along with future development, regulatory and commercialisation milestones together worth approximately $30m in addition to projected sales-based royalties. CTTQ
As the first and only four-strain influenza vaccine option for patients as young as six months of age, Fluzone Quadrivalent vaccine is the newest addition to the Fluzone